![Tomer Yossef](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tomer Yossef
Plus aucun poste en cours
Profil
Tomer Yossef served as an Independent Director at Bioblast Pharma Ltd.
before pursuing his education.
He received his undergraduate and graduate degrees from Tel-Aviv University, and also earned an MBA.
Anciens postes connus de Tomer Yossef
Sociétés | Poste | Fin |
---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Directeur/Membre du Conseil | - |
Formation de Tomer Yossef
Tel-Aviv University | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |